Stroke Center, Department of Neurology, The First Hospital of Jilin University, Changchun 130021, Jilin, China; Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, Guangdong, China.
Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, Guangdong, China.
Pharmacol Res. 2023 Jan;187:106641. doi: 10.1016/j.phrs.2022.106641. Epub 2022 Dec 29.
Treatment of acute ischemic stroke with the recombinant tissue plasminogen activator (rtPA) is associated with increased blood-brain barrier (BBB) disruption and hemorrhagic transformation. Remote ischemic conditioning (RIC) has demonstrated neuroprotective effects against acute ischemic stroke. However, whether and how RIC regulates rtPA-associated BBB disruption remains unclear. Here, a rodent model of thromboembolic stroke followed by rtPA thrombolysis at different time points was performed with or without RIC. Brain infarction, neurological outcomes, BBB permeability, and intracerebral hemorrhage were assessed. The platelet-derived growth factor CC (PDGF-CC)/PDGFRα pathway in the brain tissue, PDGF-CC levels in the skeletal muscle and peripheral blood were also measured. Furthermore, impact of RIC on serum PDGF-CC levels were measured in healthy subjects and AIS patients. Our results showed that RIC substantially reduced BBB injury, intracerebral hemorrhage, cerebral infarction, and neurological deficits after stroke, even when rtPA was administrated in a delayed therapeutic time window. Mechanistically, RIC significantly decreased PDGFRα activation in ischemic brain tissue and reduced blood PDGF-CC levels, which partially resulted from PDGF-CC reduction in the skeletal muscle of RIC-applied hindlimbs and platelets. Intravenous or intraventricular recombinant PDGF-CC supplementation abolished RIC protective effects on BBB integrity. Moreover, similar changes of PDGF-CC in serum by RIC were also observed in healthy humans and acute ischemic stroke patients. Together, our study demonstrates that RIC can attenuate rtPA-aggravated BBB disruption after ischemic stroke via reducing the PDGF-CC/PDGFRα pathway and thus supports RIC as a potential approach for BBB disruption prevention or treatment following thrombolysis.
急性缺血性脑卒中(AIS)的重组组织型纤溶酶原激活剂(rtPA)溶栓治疗与血脑屏障(BBB)破坏和出血性转化的增加有关。远程缺血预处理(RIC)已被证明对急性缺血性脑卒中具有神经保护作用。然而,RIC 是否以及如何调节 rtPA 相关的 BBB 破坏仍不清楚。在此,通过在不同时间点进行血栓栓塞性中风模型和 rtPA 溶栓治疗,观察 RIC 的作用。评估脑梗死、神经功能结局、BBB 通透性和脑出血情况。还测量了脑组织中血小板衍生生长因子 CC(PDGF-CC)/PDGFRα 通路、骨骼肌和外周血中的 PDGF-CC 水平。此外,还在健康受试者和 AIS 患者中测量了 RIC 对血清 PDGF-CC 水平的影响。我们的结果表明,RIC 可显著减轻中风后 BBB 损伤、脑出血、脑梗死和神经功能缺损,即使在 rtPA 延迟治疗时间窗内给药。其机制是 RIC 显著降低了缺血性脑组织中 PDGFRα 的激活,并降低了血液 PDGF-CC 水平,这部分归因于 RIC 应用后肢骨骼肌和血小板中 PDGF-CC 的减少。静脉内或脑室内重组 PDGF-CC 补充可消除 RIC 对 BBB 完整性的保护作用。此外,RIC 在健康人群和急性缺血性脑卒中患者血清中也观察到类似的 PDGF-CC 变化。总之,我们的研究表明,RIC 可通过降低 PDGF-CC/PDGFRα 通路来减轻 rtPA 加重的缺血性脑卒中后 BBB 破坏,因此支持 RIC 作为溶栓后预防或治疗 BBB 破坏的潜在方法。